摘要
为了检测肝细胞癌患者血清中RASSF1A和CDH13基因启动子的甲基化状态,收集肝细胞癌患者及健康对照者的血清标本,采用巢式甲基化特异性PCR(nMSP)法检测RASSF1A和CDH13基因启动子区甲基化状态.结果肝细胞癌患者血清样品中RASSF1A和CDH13基因启动子区甲基化率为53.12%和31.25%,68.75%的患者血清可以检测到异常甲基化,正常对照血清中未检测到RASSF1A和CDH13基因启动子区甲基化,RASSF1A和CDH13基因甲基化与患者的临床病理资料无明显相关性(P>0.05);表明nMSP法检测血清中RASSF1A和CDH13基因启动子区甲基化具有较高的敏感性,可为肝细胞癌的筛查、早期诊断和预后判断提供有价值的信息.
To evaluate the methylation status of the promoter region of RASSF1A and CDH13 gene using serum samples from hepatocellular carcinoma（HCC） patients,nested methylation-specific PCR（nMSP） was used to detect RASSF1A and CDH13 promoter hypermethylation in serum DNA from 32 cases of HCC,while serum samples from 20 healthy individuals were used as controls.The positive rate of promoter hyper-methylation in RASSF1A and CDH13 gene were 53.12% and 31.25% in the serum of HCC patients.Overall,68.75% patients with HCC can be detected with promoter hypermethylation in serum DNA.No aberrant promoter methylation was detected in the controls.Clinical data including age,sex,HBV,levels of AFP,clinical stages,invasion and metastasis showed no correlation with aberrant methylation of RASSF1A and CDH13（P0.05）.The data showed that it is sensitive for nMSP to detect the aberrant me-thylation in the promoter of RASSF1A and CDH13 gene in HCC.The detection of RASSF1A and CDH13 gene promoter hypermethylation in the serum of HCC patients can give useful information for the screening,early diagnosis,and prediction of prognosis of HCC.
出处
《生命科学研究》
CAS
CSCD
2011年第1期56-60,共5页
Life Science Research
基金
湖南省卫生厅科研基金资助项目(BD006090)
